Production (Stage)
MiNK Therapeutics, Inc.
INKT
$7.26
-$0.035-0.48%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 4.30M | 4.31M | 5.69M | 6.33M | 7.05M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | 118.20K | 118.20K | 180.90K | -- | -- |
| Total Operating Expenses | 11.69M | 12.98M | 14.12M | 17.46M | 20.90M |
| Operating Income | -11.69M | -12.98M | -14.12M | -17.46M | -20.90M |
| Income Before Tax | -9.74M | -10.78M | -13.78M | -17.09M | -20.59M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -9.74 | -10.78 | -13.78 | -17.09 | -20.59 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -9.74M | -10.78M | -13.78M | -17.09M | -20.59M |
| EBIT | -11.69M | -12.98M | -14.12M | -17.46M | -20.90M |
| EBITDA | -11.42M | -12.71M | -13.90M | -17.25M | -20.68M |
| EPS Basic | -2.50 | -2.91 | -3.86 | -4.89 | -5.96 |
| Normalized Basic EPS | -1.83 | -2.11 | -2.45 | -3.09 | -3.73 |
| EPS Diluted | -3.13 | -3.53 | -3.86 | -4.89 | -5.96 |
| Normalized Diluted EPS | -1.83 | -2.11 | -2.45 | -3.09 | -3.73 |
| Average Basic Shares Outstanding | 15.59M | 15.09M | 14.59M | 14.08M | 13.81M |
| Average Diluted Shares Outstanding | 15.59M | 15.09M | 14.59M | 14.08M | 13.81M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |